Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
    • Clinic Portal
      • +0034963905310
    • Request Information
    • +34 96 390 53 10
    InternationalInternational
    • Country/Region
    • We guide you
      • Fertility
        • What to do if…
      • Prevent Inherited Diseases
        • Carrier Genetic Test
      • Worry-free Pregnancy
        • NACE
        • Prenatal Diagnostics
        • Newborn Health
    • Reproductive Health
      • Specialists
        • ALICE
        • EMMA
        • ERA
        • EndomeTRIO
        • EMBRACE
        • CGT
        • NACE
        • Zenit
        • PGT-A
        • PGT-M
        • POC
        • SAT
        • Newborn Screening
      • Patients
        • ALICE
        • EMMA
        • ERA
        • EndomeTRIO
        • EMBRACE
        • CGT
        • NACE
        • Zenit
        • PGT-A
        • PGT-M
        • SAT
        • POC
    • Diagnostics
    • About us
      • Igenomix Research
      • About Igenomix
    • Academy
    • Blog
        Genomics Precision Diagnostic > Cardiology > Arrhythmogenic Right Ventricular Dysplasia Precision Panel

        Arrhythmogenic Right Ventricular Dysplasia Precision Panel

        Arrhythmogenic Right Ventricular Dysplasia (ARVD) is an inherited cardiomyopathy characterized by structural and functional abnormalities in the right ventricle, resulting in ventricular arrhythmias.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Arrhythmogenic Right Ventricular Dysplasia (ARVD) is an inherited cardiomyopathy characterized by structural and functional abnormalities in the right ventricle, resulting in ventricular arrhythmias. It is a rare but important cause of sudden arrhythmic death in young and healthy personas, as well as a subtle cause of congestive heart failure, which can lead to temporary incapacitation with severe consequences. Structurally, although less prominent than right ventricle, left ventricle can be also affected by myocyte loss and fibrosis, increasing the likelihood of this condition with age. This fact suggests that ARVD is a progressive disease. Affected individuals do not have evidence of the disease at birth, and typically the disease starts to manifest clinically at approximately 12 or 13 years of age, with the mean age at diagnosis in the early 30s. The mode of inheritance is mainly autosomal dominant. 

        • The Igenomix Arrhythmogenic Right Ventricular Dysplasia Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of cardiomyopathy, ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

        Indication

        • The Igenomix Arrhythmogenic Right Ventricular Dysplasia Precision Panel is indicated for those patients with a clinical diagnosis or suspicion presenting with or without the following manifestations: 
          • Palpitations 
          • Arrhythmias during exercise 
          • Syncope 
          • Atypical chest pain 
          • Dyspnea 
          • Right Ventricular Failure 

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
        • Early initiation of multidisciplinary treatment to reduce mortality, prevent disease progression, improve symptoms and quality of life, limit heart failure symptoms and improve functional capacity. Pharmacological treatment includes Beta-blocker therapy and antiarrhythmic agents such as flecainide, propafenone, sotalol and amiodarone, to prevent ventricular tachycardia. In most severe cases, an implantable cardioverter-defibrillator or even a heart transplantation might be needed. Lifestyle changes will always help getting a better prognosis.  
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
        • Improvement of delineation of genotype-phenotype correlation. 

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        Gemayel, C., Pelliccia, A., & Thompson, P. D. (2001). Arrhythmogenic right ventricular cardiomyopathy. Journal of the American College of Cardiology, 38(7), 1773–1781. https://doi.org/10.1016/s0735-1097(01)01654-0 

        Sen-Chowdhry, S., Lowe, M. D., Sporton, S. C., & McKenna, W. J. (2004). Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. The American journal of medicine, 117(9), 685–695. https://doi.org/10.1016/j.amjmed.2004.04.028 

        Hulot, J. S., Jouven, X., Empana, J. P., Frank, R., & Fontaine, G. (2004). Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation, 110(14), 1879–1884. https://doi.org/10.1161/01.CIR.0000143375.93288.82 

        Corrado, D., Fontaine, G., Marcus, F. I., McKenna, W. J., Nava, A., Thiene, G., & Wichter, T. (2000). Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation, 101(11), E101–E106. https://doi.org/10.1161/01.cir.101.11.e101 

        McKenna, W. J., Thiene, G., Nava, A., Fontaliran, F., Blomstrom-Lundqvist, C., Fontaine, G., & Camerini, F. (1994). Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. British heart journal, 71(3), 215–218. https://doi.org/10.1136/hrt.71.3.215 

        descargar

        Detail description

        Download

        Request Information


        WE GUIDE YOU

        Fertility
        Inherited diseases prevention
        Healthy pregnancy

        To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

        OUR SERVICES

        Genetic solutions
        For patients
        How to send a sample?
        User manual

        ABOUT US

        About Igenomix
        Contact
        Quality
        Complaints
        Work with us

        FOLLOW IGENOMIX

          + 96 390 53 10
          Write us
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Country/Region

        [2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

        Request Information


        • We guide you
          • Fertility
            • What to do if…
          • Prevent Inherited Diseases
            • Carrier Genetic Test
          • Worry-free Pregnancy
            • NACE
            • Prenatal Diagnostics
            • Newborn Health
        • Reproductive Health
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • Zenit
            • PGT-A
            • PGT-M
            • POC
            • SAT
            • Newborn Screening
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • Zenit
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • Diagnostics
        • About us
          • Igenomix Research
          • About Igenomix
        • Academy
        • Blog
        • Country/Region
        • +34 96 390 53 10
        • Clinic Portal
        • Request Information

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        International
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

        3rd Party Cookies

        This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

        Keeping this cookie enabled helps us to improve our website.

        Please enable Strictly Necessary Cookies first so that we can save your preferences!

        Cookie Policy

        More information about our Cookie Policy